Strides Pharma Science Limited

NSE STAR.NS

Strides Pharma Science Limited Net Cash Used For Investing Activities for the year ending March 31, 2024: USD -18.01 M

Strides Pharma Science Limited Net Cash Used For Investing Activities is USD -18.01 M for the year ending March 31, 2024, a -148.95% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Strides Pharma Science Limited Net Cash Used For Investing Activities for the year ending March 31, 2023 was USD 36.80 M, a 335.35% change year over year.
Strides Pharma Science Limited Net Cash Used For Investing Activities for the year ending March 31, 2022 was USD -15.64 M, a 78.02% change year over year.
Strides Pharma Science Limited Net Cash Used For Investing Activities for the year ending March 31, 2021 was USD -71.13 M, a -141.04% change year over year.
Strides Pharma Science Limited Net Cash Used For Investing Activities for the year ending March 31, 2020 was USD 173.33 M, a 911.15% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NSE: STAR.NS

Strides Pharma Science Limited

CEO	Mr. Badree Komandur
IPO Date	June 26, 2002
Location	India
Headquarters	Strides House
Employees	3,065
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.

Key trends

Past 5 years